Introduction: Smoking is a risk factor that significantly affects general and oral health by altering the oral environment, increasing plague build-up, and reducing blood flow in the gums, leading to tooth decay and periodontal disease. Therefore, this study investigated the association between smoking behaviors, such as smoking duration and cessation, and oral health problems.
Methods: This study analyzed a secondary dataset of the Korea National Health and Nutrition Examination Survey (2019-2021) that included 6150 men and 7574 women. Individuals were classified as current smokers if they were currently smoking regular cigarettes, heated tobacco products, or electronic cigarettes. Oral health problems included toothaches and chewing difficulties. Multiple logistic regression was used to calculate adjusted odds ratios (AORs) and 95% confidence intervals (CIs) for the association between smoking behavior and oral health problems.
Results: Among participants of both sexes, current smokers had more oral health problems compared with non-smokers (men, AOR=1.60; 95% CI: 1.35-1.89; women, AOR=1.91; 95% CI: 1.33-2.71), as did ex-smokers (men, AOR=1.39; 95% CI: 1.18-1.63; women, AOR=1.47; 95% CI: 1.18-1.83). The longer the smoking cessation period, the lower was the prevalence of oral health problems. Additionally, high pack-years were associated with oral health issues. Regular cigarettes were more likely to cause problems than e-cigarettes (men, AOR=1.56; 95% CI: 1.31-1.86; women, AOR=1.96; 95% CI: 1.53-2.52), while vaping (men, AOR=1.36; 95% CI: 1.05-1.74; women, AOR=1.64; 95% CI: 1.06-2.53) and dual smoking (men, AOR=1.57; 95% CI: 1.14-2.16; women, AOR=1.97; 95% CI: 1.10-3.50) were also associated with oral health issues.
Conclusions: This study confirmed that smoking is strongly associated with oral health problems. Public health efforts should focus on prevention and tailored interventions to support quitting and improve oral health outcomes in both current and ex-smokers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887038 | PMC |
| http://dx.doi.org/10.18332/tid/200693 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Body dysmorphic disorder (BDD), characterized by an obsessive focus on perceived flaws in appearance and affects approximately 0.7% through 2.4% of the general population, with dental-related concerns accounting for 20% of cases.
View Article and Find Full Text PDFAntitumor efficacy of intermittent low-dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche.
Int J Cancer
March 2025
Center for Epigenetics & Disease Prevention, Texas A&M HEALTH, and Department of Translational Medical Sciences, Texas A&M University Naresh K. Vashisht College of Medicine, Houston, Texas, USA.
A previously reported clinical trial in familial adenomatous polyposis (FAP) patients treated with erlotinib plus sulindac (ERL + SUL) highlighted immune response/interferon-γ signaling as a key pathway. In this study, we combine intermittent low-dose ERL ± SUL treatment in the polyposis in rat colon (Pirc) model with mechanistic studies on tumor-associated immune modulation. At clinically relevant doses, short-term (16 weeks) and long-term (46 weeks) ERL ± SUL administration results in near-complete tumor suppression in Pirc colon and duodenum (p < 0.
View Article and Find Full Text PDFDiagnosis and Treatment of Gestational Diabetes Mellitus: A National Survey of Physician Practices.
J Womens Health (Larchmt)
March 2025
Division of Maternal-Fetal Medicine and Obstetrics, Stanford University School of Medicine, Stanford, California, USA.
We aimed to identify changes in United States practice patterns in gestational diabetes mellitus (GDM) diagnosis and treatment following publication of the 2008 Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study that supported transition toward a 2-hour oral glucose tolerance test. A total of 1,030 U.S.
View Article and Find Full Text PDFStatins as an Adjunctive Antithrombotic Agent in Thrombotic Antiphospholipid Syndrome: Mechanisms and Clinical Implications.
Cells
February 2025
Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
The thrombotic physiopathology of antiphospholipid syndrome (APS) is complex, heterogeneous, and dynamic. While venous thromboembolism (VTE) is the most common initial presentation, arterial thrombotic events (ATE) become more frequent in advanced stages and are associated with high morbidity and mortality. Despite the use of oral anticoagulants (OACs), thrombotic APS remains associated with a high risk of recurrent thrombosis.
View Article and Find Full Text PDFFinerenone Alleviates Over-Activation of Complement C5a-C5aR1 Axis of Macrophages by Regulating G Protein Subunit Alpha i2 to Improve Diabetic Nephropathy.
Cells
February 2025
Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China.
Diabetic nephropathy (DN), one of the most common complications of diabetes mellitus (DM), accounts for a major cause of chronic kidney disease (CKD) worldwide, with a complicated pathogenesis and limited effective strategies nowadays. The mineralocorticoid receptor (MR) is a classical ligand-activated nuclear transcription factor. It is expressed in the renal intrinsic and immune cells, especially macrophages.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!